Overview of Dr. Houghton
Dr. Alan Houghton is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from University of Connecticut and has been in practice 43 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1979
University of ConnecticutResidency, Internal Medicine, 1976 - 1977
Sidney Kimmel Medical College at Thomas Jefferson UniversityInternship, Transitional Year, 1974 - 1975- Uconn School Of MedicineClass of 1974
Certifications & Licensure
CT State Medical License 1976 - 2021
NY State Medical License 1979 - 2014
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1989
Clinical Trials
- Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity Start of enrollment: 2003 Dec 01
- Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity Start of enrollment: 2006 May 01
- Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma Start of enrollment: 2007 Oct 01
Publications & Presentations
PubMed
- 3 citationsCyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitnessDaniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, Andrew Chow, Levi Mangarin
JCI Insight. 2021-10-22 - 94 citationsBlockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironmentSadna Budhu, David Schaer, Yongbiao Li, Ricardo Toledo-Crow, Katherine S. Panageas
Science Signaling. 2017-08-29 - 12 citationsEnhanced responses to tumor immunization following total body irradiation are time-dependent.Adi Diab, Robert R. Jenq, Gabrielle Rizzuto, Adam D. Cohen, Deonka Huggins
Plos One. 2013-12-12
Press Mentions
Immunotherapy Innovator Jedd Wolchok HonoredApril 11th, 2015
Grant Support
- Immunization Against Melanoma Differentiation AntigensNational Cancer Institute2000–2012
- Genetic Approaches To Immune AdjuvantsNational Cancer Institute2006–2010
- DNA Vaccination Against MelanomaNational Cancer Institute2008–2009
- Administrative CoreNational Cancer Institute2008–2009
- Targeted Antigen Receptor Treatment Of CancerNational Cancer Institute2005–2007
- Immunology Research TrainingNational Cancer Institute1997–2005
- Biological Approaches To The Treatment Of CancerNational Cancer Institute2000–2004
- DNA Vaccination With Altered AntigensNational Cancer Institute2000–2002
- Dendritic Cells For Induction Of Cancer ImmunityNational Cancer Institute2000–2002
- Clinical Studies/TrialsNational Cancer Institute2000–2002
- ImmunologyNational Cancer Institute1998–2002
- Genetically Modified Dendritic Cells For Induction Of Cancer ImmunityNational Cancer Institute1997–1999
- Monoclonal Antibody Therapy Against Ganglioside AntigensNational Cancer Institute1996–1999
- Biological Approaches To Treatment Of CancerNational Cancer Institute1995–1999
- Immunization Against Cancer Differentiation AntigensNational Cancer Institute1996–1998
- Monoclonal Antibodies And Vaccines In Cancer TherapyNational Cancer Institute1994
- Active Immunotherapy Of MelanomaNational Cancer Institute1992–1994
- Specificity Of Monoclonal Antibodies To Human CancerNational Cancer Institute1985
- Diagnostic And Therapeutic Trials With Monoclonal AntibodiesNational Cancer Institute1985
